65~75 岁患者
75~80 岁以上患者
几个 NSCLC 免疫治疗关键试验中 75 岁以上患者的数据结论不一:
晚期肺癌患者中 20%~40% 的 PS 评分为 2 分,而老年患者状况不佳的比例更高,因此除了年龄外,PS 评分是决定老年患者治疗时必须考虑的因素。
免疫治疗对于老年患者安全性良好,但是疗效要区分来看:75 岁以下患者使用免疫治疗和总体人群疗效类似,而 75 岁以上则获益有限,特别是 PS 2 分老年患者。
参考文献
1 Passaro A. Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. J Clin Oncol 2019
2 Zheng SY. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. Clin Transl Oncol 2019
3 Nosaki K. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung can 1 Passaro A. Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. J Clin Oncol 2019
2 Zheng SY. The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. Clin Transl Oncol 2019
3 Nosaki K. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019
4 Grossi F. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer 2018
5 Lichtenstein MRL. Impact of Age on Outcomes with Immunotherapy in Patients with Non–Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019
6 Spigel DR. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status(CheckMate 153). J Thorac Oncol 2019
7 Lung Unit. A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers 2018
8 Middleton G. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020 cer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019
4 Grossi F. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer 2018
5 Lichtenstein MRL. Impact of Age on Outcomes with Immunotherapy in Patients with Non–Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019
6 Spigel DR. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status(CheckMate 153). J Thorac Oncol 2019
7 Lung Unit. A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers 2018
8 Middleton G. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020
联系客服